Press Releases

Date Title and Summary Additional Formats
Toggle Summary Mylan to Release Third Quarter 2018 Financial Results on November 5, 2018
HERTFORDSHIRE, England and PITTSBURGH , Oct. 18, 2018 /PRNewswire/ -- Global pharmaceutical company Mylan N.V. (NASDAQ: MYL) today announced that it will release its third quarter 2018 financial results, on Mon., Nov. 5 , after the close of the U.S. financial markets. The company also will host a
View HTML
Toggle Summary Mylan Prevails in Copaxone® 40mg/mL Litigation Against Teva in U.S. Appellate Court
Court Affirms Prior Decisions Finding Copaxone® 40 mg/mL Patents Invalid HERTFORDSHIRE, England and PITTSBURGH , Oct. 12, 2018 /PRNewswire/ -- Mylan N.V . (NASDAQ: MYL) today announced that the United States Court of Appeals for the Federal Circuit has affirmed the District of Delaware's decision
View HTML
Toggle Summary Mylan Launches Vivarin™ Caffeine Gum to Provide a Boost of Caffeine Wherever, Whenever
HERTFORDSHIRE, England and PITTSBURGH, Oct. 12, 2018 / PRNewswire / --  Mylan N.V. (NASDAQ: MYL) today announced the launch of Vivarin ™  Caffeine Gum to provide adults (18 and older) a convenient way to get an appropriate boost of caffeine with a burst of mint flavor anywhere and anytime you need
View HTML
Toggle Summary Theravance Biopharma and Mylan Report Positive New Data from Multiple Studies of YUPELRI™ (revefenacin) at the 2018 CHEST Annual Meeting
Additional Analyses of Phase 3 Program Data Highlight Efficacy Advantages for 175 mcg/day of YUPELRI in Key Patient Subgroups, Demonstrate Acceptable Cardiovascular Safety Profile DUBLIN and HERTFORDSHIRE, England and PITTSBURGH, Oct. 11, 2018 /PRNewswire/ -- Theravance Biopharma, Inc.
View HTML
Toggle Summary Theravance Biopharma and Mylan to Present New Data from Studies of YUPELRI™ (revefenacin) at the 2018 CHEST Annual Meeting
Presentations Highlight Data of YUPELRI Compared with Tiotropium in Subpopulation of COPD Patients with Suboptimal Peak Inspiratory Flow Rates, Report Additional Data from Pivotal Phase 3 Program in Patients with Moderate to Very Severe COPD DUBLIN and HERTFORDSHIRE, England and PITTSBURGH , Oct.
View HTML
Toggle Summary Mylan Extends Commitment to Fight HIV/AIDS by Partnering with Atomo Diagnostics to Expand Access to HIV Self-Testing in Low- and Middle-Income Countries
HERTFORDSHIRE,  England and PITTSBURGH and SYDNEY , Sept. 24, 2018 /PRNewswire/ -- Global pharmaceutical company Mylan N.V. (NASDAQ: MYL) and medical device company Atomo Diagnostics today announced a strategic partnership to commercialize CE-Marked  in vitro HIV rapid diagnostic tests for
View HTML
Toggle Summary Mylan and Biocon Announce Positive CHMP Opinion for Fulphila®, Biosimilar Pegfilgrastim
HERTFORDSHIRE, England and PITTSBURGH and BENGALURU, India , Sept. 21, 2018 /PRNewswire/ --   Mylan N.V. (NASDAQ: MYL) and Biocon Ltd. (BSE code: 532523, NSE: BIOCON ) today announced that the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) has issued a positive
View HTML
Toggle Summary Mylan Launches Authorized Generic of Ampyra® Tablets
- Mylan's Dalfampridine Extended-Release Tablets, 10 mg, are indicated for patients with multiple sclerosis - HERTFORDSHIRE, England and PITTSBURGH, Sept. 21, 2018 /PRNewswire/ -- Global pharmaceutical company Mylan N.V. (NASDAQ: MYL) today announced the U.S.
View HTML
Toggle Summary Mylan and Fujifilm Kyowa Kirin Biologics Receive European Marketing Authorization for Hulio®, Biosimilar Adalimumab
HERTFORDSHIRE , England and PITTSBURGH and TOKYO , Sept. 20, 2018 /PRNewswire/ --  Mylan N.V.  (NASDAQ: MYL) and Fujifilm Kyowa Kirin Biologics Co., Ltd. today announced that the European Commission (EC) has granted marketing authorization for Hulio ® (Product Code: FKB327), a biosimilar to
View HTML
Toggle Summary Theravance Biopharma and Mylan Report New Data from Phase 3 Studies of YUPELRI™ (revefenacin) in Oral Presentation at the European Respiratory Society International Congress
Reduction in Rates of COPD Exacerbations Observed in COPD Patients Treated with YUPELRITM Compared to Placebo and Tiotropium (Spiriva® HandiHaler®) DUBLIN and HERTFORDSHIRE, England and PITTSBURGH , Sept. 17, 2018 /PRNewswire/ --  Theravance Biopharma, Inc.
View HTML